<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984188</url>
  </required_header>
  <id_info>
    <org_study_id>20201523</org_study_id>
    <secondary_id>1K23HL146946-01</secondary_id>
    <secondary_id>IRB00209008</secondary_id>
    <nct_id>NCT03984188</nct_id>
  </id_info>
  <brief_title>Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD</brief_title>
  <official_title>Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide,&#xD;
      and over 90% of COPD-related deaths occurring in low- and middle-income countries (LMICs).&#xD;
      Household air pollution (HAP) - from burning solid fuels such as wood, dung, agricultural&#xD;
      crop waste, and coal for energy - is the primary risk factor for COPD in these settings.&#xD;
      Biomass-related COPD has a distinct histopathology, phenotype and inflammatory profile when&#xD;
      compared to tobacco mediated COPD. Despite the high global burden of biomass-related disease,&#xD;
      little is known about the effectiveness of pharmacotherapies for biomass-related COPD; to&#xD;
      date, no clinical trials have focused specifically on treatment of biomass-related COPD. This&#xD;
      study proposes to assess the health impact of biomass-related COPD and test the effectiveness&#xD;
      of low dose theophylline compared to standard therapy among adults with biomass-related COPD&#xD;
      in Uganda with the aim to assess whether low-dose theophylline improves respiratory symptoms,&#xD;
      decreases the inflammatory profile of serum biomarkers and whether administration attenuates&#xD;
      the effect of HAP on lung function. The study additionally aims to assess whether low-dose&#xD;
      theophylline is a cost-effective intervention based on the incremental cost-effectiveness&#xD;
      ratio and a range of willingness to pay thresholds.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in St. George Respiratory Questionnaire (SGRQ) Scores</measure>
    <time_frame>Baseline to 6 months, Baseline to 1 year</time_frame>
    <description>The SGRQ comprises of 50 items and consists of two parts. The first part pertains to symptoms and the second pertains to functional status as well as social and psychological impact of disease. Overall scores ranges between 0 and 100 with higher scores indicating more limitations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Baseline to 6 months, Baseline to 1 year</time_frame>
    <description>FEV1 (L) as measured through spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced vital capacity (FVC)</measure>
    <time_frame>Baseline to 6 months, Baseline to 1 year</time_frame>
    <description>FVC (L) as measured through spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak expiratory flow (PEF)</measure>
    <time_frame>Baseline to 6 months, Baseline to 1 year</time_frame>
    <description>PEF (L/min) as measured through spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood levels of high sensitivity C reactive protein (hs-CRP)</measure>
    <time_frame>Baseline to 6 months, Baseline to 1 year</time_frame>
    <description>Blood levels of hs-CRP (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood levels of fibrinogen</measure>
    <time_frame>Baseline to 6 months, Baseline to 1 year</time_frame>
    <description>Blood levels of fibrinogen (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form 36 (SF-36) Questionnaire Scores</measure>
    <time_frame>Baseline to 6 months, Baseline to 1 year</time_frame>
    <description>The SF-36 consists of eight scaled domains (vitality, physical functioning, body pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health) each transformed into a 0-100 scale. Lower scores signify higher levels of disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>COPD</condition>
  <condition>COPD Exacerbation</condition>
  <condition>COPD Exacerbation Acute</condition>
  <condition>Pollution Related Respiratory Disorder</condition>
  <condition>Pollution; Exposure</condition>
  <arm_group>
    <arm_group_label>Low-dose Theophylline Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant in this group will receive low-dose theophylline in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment, over a one year period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant in this group will receive a placebo in addition to standard care, per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline ER</intervention_name>
    <description>200 mg extended release (ER) low-dose theophylline taken orally daily</description>
    <arm_group_label>Low-dose Theophylline Group</arm_group_label>
    <other_name>Low-dose Theophylline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Manufactured methylcellulose placebo tablet taken orally daily</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care Treatment</intervention_name>
    <description>Per World Health Organization (WHO) guidelines for management of Chronic Obstructive Pulmonary Disease (COPD) treatment</description>
    <arm_group_label>Low-dose Theophylline Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 40 years&#xD;
&#xD;
          2. Full-time resident of study area&#xD;
&#xD;
          3. Post-bronchodilator FEV1/FVC &lt; the lower limit of normal of the Global Lung Initiative&#xD;
             Mixed Ethnic reference population&#xD;
&#xD;
          4. Grade B-D COPD&#xD;
&#xD;
          5. Daily biomass exposure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Plans to move within one year&#xD;
&#xD;
          2. Uncontrolled hypertension&#xD;
&#xD;
          3. Pregnancy (assessed by urine pregnancy test among women of childbearing age/menstrual&#xD;
             history)&#xD;
&#xD;
          4. Current use of chronic respiratory medications (Long acting Beta 2 Antagonists (LABA),&#xD;
             Long-acting muscarinic antagonist (LAMA), inhaled corticosteroid (ICS))&#xD;
&#xD;
          5. History of post-treatment pulmonary tuberculosis&#xD;
&#xD;
          6. ≥10 pack year tobacco smoking history&#xD;
&#xD;
          7. Known intolerance or contraindication to theophylline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trishul Siddharthan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trishul Siddharthan, MD</last_name>
    <phone>305-243-6388</phone>
    <email>t.siddharthan@umiami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Makerere Lung Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Alupo, MMED</last_name>
      <phone>+256701124540</phone>
    </contact>
    <investigator>
      <last_name>Patricia Alupo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nakaseke Hospital</name>
      <address>
        <city>Nakaseke</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Alupo, MMED</last_name>
      <phone>+256701124540</phone>
      <email>alupopat@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Trishul Siddharthan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Bonjour S, Adair-Rohani H, Wolf J, Bruce NG, Mehta S, Prüss-Ustün A, Lahiff M, Rehfuess EA, Mishra V, Smith KR. Solid fuel use for household cooking: country and regional estimates for 1980-2010. Environ Health Perspect. 2013 Jul;121(7):784-90. doi: 10.1289/ehp.1205987. Epub 2013 May 3.</citation>
    <PMID>23674502</PMID>
  </reference>
  <reference>
    <citation>Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, Gutierrez L, Miranda JJ, Bernabe-Ortiz A, Alam D, Kirenga B, Jones R, van Gemert F, Wise RA, Checkley W. Association between Household Air Pollution Exposure and Chronic Obstructive Pulmonary Disease Outcomes in 13 Low- and Middle-Income Country Settings. Am J Respir Crit Care Med. 2018 Mar 1;197(5):611-620. doi: 10.1164/rccm.201709-1861OC.</citation>
    <PMID>29323928</PMID>
  </reference>
  <reference>
    <citation>Moran-Mendoza O, Pérez-Padilla JR, Salazar-Flores M, Vazquez-Alfaro F. Wood smoke-associated lung disease: a clinical, functional, radiological and pathological description. Int J Tuberc Lung Dis. 2008 Sep;12(9):1092-8.</citation>
    <PMID>18713510</PMID>
  </reference>
  <reference>
    <citation>Pérez-Padilla R, Ramirez-Venegas A, Sansores-Martinez R. Clinical Characteristics of Patients With Biomass Smoke-Associated COPD and Chronic Bronchitis, 2004-2014. Chronic Obstr Pulm Dis. 2014 May 6;1(1):23-32. doi: 10.15326/jcopdf.1.1.2013.0004. Review.</citation>
    <PMID>28848808</PMID>
  </reference>
  <reference>
    <citation>Aït-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ. 2001;79(10):971-9. Epub 2001 Nov 1.</citation>
    <PMID>11693980</PMID>
  </reference>
  <reference>
    <citation>Beran D, Zar HJ, Perrin C, Menezes AM, Burney P; Forum of International Respiratory Societies working group collaboration. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med. 2015 Feb;3(2):159-170. doi: 10.1016/S2213-2600(15)00004-1. Review.</citation>
    <PMID>25680912</PMID>
  </reference>
  <reference>
    <citation>Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc. 2005;2(4):334-9; discussion 340-1. Review.</citation>
    <PMID>16267358</PMID>
  </reference>
  <reference>
    <citation>Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010 Jun;137(6):1338-44. doi: 10.1378/chest.09-2363. Epub 2010 Mar 18.</citation>
    <PMID>20299628</PMID>
  </reference>
  <reference>
    <citation>Rivera RM, Cosio MG, Ghezzo H, Salazar M, Pérez-Padilla R. Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. Int J Tuberc Lung Dis. 2008 Aug;12(8):972-7.</citation>
    <PMID>18647460</PMID>
  </reference>
  <reference>
    <citation>Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007 Apr;85(4):279-88.</citation>
    <PMID>17546309</PMID>
  </reference>
  <reference>
    <citation>Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, Zheng J, Zhong N, Ran P. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006 Sep;11(5):603-10.</citation>
    <PMID>16916334</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Trishul Siddharthan</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical</investigator_title>
  </responsible_party>
  <keyword>Biomass Associated COPD</keyword>
  <keyword>Low-dose Theophylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

